Mizuho Securities analyst Salim Syed maintained a Buy rating on Amgen Inc (AMGN) today and set a price target of $208. The company’s shares closed on Thursday at $177.47.
According to TipRanks.com, Syed is a 1-star analyst with an average return of -3.6% and a 35.9% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Atara Biotherapeutics, and Wave Life Sciences.
Currently, the analyst consensus on Amgen Inc is a Moderate Buy with an average price target of $214.30, representing a 20.8% upside. In a report issued on April 10, Jefferies also maintained a Buy rating on the stock with a $230 price target.
See today’s analyst top recommended stocks >>
Amgen Inc’s market cap is currently $111.7B and has a P/E ratio of 14.08. The company has a Price to Book ratio of 8.94.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
